280 related articles for article (PubMed ID: 28814801)
21. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
[TBL] [Abstract][Full Text] [Related]
22. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
23. Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model.
Ciarlone SL; Wang X; Rogawski MA; Weeber EJ
Neuropharmacology; 2017 Apr; 116():142-150. PubMed ID: 27986596
[TBL] [Abstract][Full Text] [Related]
24. Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.
Sidorov MS; Judson MC; Kim H; Rougie M; Ferrer AI; Nikolova VD; Riddick NV; Moy SS; Philpot BD
J Neurosci; 2018 Mar; 38(11):2671-2682. PubMed ID: 29431654
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome.
Berg EL; Petkova SP; Born HA; Adhikari A; Anderson AE; Silverman JL
Mol Autism; 2021 Sep; 12(1):59. PubMed ID: 34526125
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a TrkB agonist on spatial and motor learning in the
Schultz MN; Crawley JN
Learn Mem; 2020 Sep; 27(9):346-354. PubMed ID: 32817301
[TBL] [Abstract][Full Text] [Related]
27. Neuronal overexpression of Ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome.
Copping NA; Christian SGB; Ritter DJ; Islam MS; Buscher N; Zolkowska D; Pride MC; Berg EL; LaSalle JM; Ellegood J; Lerch JP; Reiter LT; Silverman JL; Dindot SV
Hum Mol Genet; 2017 Oct; 26(20):3995-4010. PubMed ID: 29016856
[TBL] [Abstract][Full Text] [Related]
28. Adult
Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
[TBL] [Abstract][Full Text] [Related]
29. Flurothyl-induced seizure paradigm revealed higher seizure susceptibility in middle-aged Angelman syndrome mouse model.
Egawa K; Nakakubo S; Kimura S; Goto T; Manabe A; Shiraishi H
Brain Dev; 2021 Apr; 43(4):515-520. PubMed ID: 33408038
[TBL] [Abstract][Full Text] [Related]
30. Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume, and Microcephaly in Angelman Syndrome Model Mice.
Judson MC; Burette AC; Thaxton CL; Pribisko AL; Shen MD; Rumple AM; Del Cid WA; Paniagua B; Styner M; Weinberg RJ; Philpot BD
J Neurosci; 2017 Aug; 37(31):7347-7361. PubMed ID: 28663201
[TBL] [Abstract][Full Text] [Related]
31. Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.
Dutta R; Crawley JN
Neuroscience; 2020 Oct; 445():163-171. PubMed ID: 31730795
[TBL] [Abstract][Full Text] [Related]
32. Sex-Dependent Sensory Phenotypes and Related Transcriptomic Expression Profiles Are Differentially Affected by Angelman Syndrome.
Koyavski L; Panov J; Simchi L; Rayi PR; Sharvit L; Feuermann Y; Kaphzan H
Mol Neurobiol; 2019 Sep; 56(9):5998-6016. PubMed ID: 30706369
[TBL] [Abstract][Full Text] [Related]
33. Angelman syndrome - insights into a rare neurogenetic disorder.
Buiting K; Williams C; Horsthemke B
Nat Rev Neurol; 2016 Oct; 12(10):584-93. PubMed ID: 27615419
[TBL] [Abstract][Full Text] [Related]
34. Excessive Laughter-like Vocalizations, Microcephaly, and Translational Outcomes in the
Berg EL; Jami SA; Petkova SP; Berz A; Fenton TA; Lerch JP; Segal DJ; Gray JA; Ellegood J; Wöhr M; Silverman JL
J Neurosci; 2021 Oct; 41(42):8801-8814. PubMed ID: 34475199
[TBL] [Abstract][Full Text] [Related]
35. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.
Lee D; Chen W; Kaku HN; Zhuo X; Chao ES; Soriano A; Kuncheria A; Flores S; Kim JH; Rivera A; Rigo F; Jafar-Nejad P; Beaudet AL; Caudill MS; Xue M
Elife; 2023 Jan; 12():. PubMed ID: 36594817
[No Abstract] [Full Text] [Related]
36. Towards an understanding of Angelman syndrome in mice studies.
Yang X
J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793
[TBL] [Abstract][Full Text] [Related]
37. From electrophysiology to chromatin: a bottom-up approach to Angelman syndrome.
Dan B; Servais L; Boyd SG; Wagstaff J; Cheron G
Ann N Y Acad Sci; 2004 Dec; 1030():599-611. PubMed ID: 15659843
[TBL] [Abstract][Full Text] [Related]
38. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.
Dodge A; Peters MM; Greene HE; Dietrick C; Botelho R; Chung D; Willman J; Nenninger AW; Ciarlone S; Kamath SG; Houdek P; Sumová A; Anderson AE; Dindot SV; Berg EL; O'Geen H; Segal DJ; Silverman JL; Weeber EJ; Nash KR
Autism Res; 2020 Mar; 13(3):397-409. PubMed ID: 31961493
[TBL] [Abstract][Full Text] [Related]
39. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
40. Analysis of cerebellar function in Ube3a-deficient mice reveals novel genotype-specific behaviors.
Heck DH; Zhao Y; Roy S; LeDoux MS; Reiter LT
Hum Mol Genet; 2008 Jul; 17(14):2181-9. PubMed ID: 18413322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
